Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 4499-4510

  Cai, Lulu ^a,c   Wang, Xianhuo ^d   Wang, Wenwen ^a   Qiu, Neng ^a   Wen, Jiaolin ^a   Duan, Xingmei ^a   Li, Xia ^a   Chen, Xiang ^a   Yang, Li ^a   Qian, Zhiyong ^a   Wei, Yuquan ^a   Chen, Lijuan ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Liposomes; Paclitaxel; Poly(ethylene glycol); Targeted drug delivery; Truncated fibroblast growth factor fragment

Indexed keywords

CHOLESTEROL; DISTEAROYLPHOSPHATIDIC ACID; FIBROBLAST GROWTH FACTOR RECEPTOR; MACROGOL; PACLITAXEL; PHOSPHATIDYLCHOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RELEASE; DRUG STABILITY; DRUG TUMOR LEVEL; ENCAPSULATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MELANOMA B16; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BINDING SITES; CELL LINE, TUMOR; CHOLESTEROL; DRUG STABILITY; FEMALE; HUMANS; LIGANDS; LIPOSOMES; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PACLITAXEL; PEPTIDES; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; RANDOM ALLOCATION; RECEPTORS, FIBROBLAST GROWTH FACTOR; TISSUE DISTRIBUTION;

MUS;

EID: 84870371340     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S32817     Document Type: Article

References (60)

1. Chervinsky D, Brecher M, Hoelcle M. Cremophor-EL enhances Taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell line. Anticancer Res. 1993;13:93-96.
2. Webster L, Linsenmeyer M, Millward M, Morton C, Bishop J, Woodcock D. Measurement of Cremophor EL following Taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst. 1993;85:1685-1690.
3. Fjällskog ML, Frii L, Bergh J. Is Cremophor EL, solvent for paclitaxel, cytotoxic? Lancet. 1993;342:873.
4. Rowinsky E, Eisenhauer E, Chaudhry V, Arbuck S, Donehower R. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol. 1993;20(4 Suppl 3):1-15.
5. Dorr RT. Pharmacology and toxicology of Cremophor EL diluent. Ann Pharmacother. 1994;28(5):S11-S14.
6. Goldspiel BR. Pharmaceutical issues: preparation, administration, stability, and compatibility with other medications. Ann Pharmacother. 1994;28:23-26.
7. Song D, Hsu LF, Au JLS. Binding of Taxol to plastic and glass containers and protein under in vitro conditions. J Pharm Sci. 1996;85:29-31.
8. Kongshaug M, Cheng LS, Moan J, Rimington C. Interaction of Cremophor EL with human plasma. Int J Biochem. 1991;23:473-478.
9. Sykes E, Woodburn K, Decker D, Kessel D. Effects of Cremophor EL on distribution of Taxol to serum lipoproteins. Br J Cancer. 1994;70: 401-404.
10. Gao JF, Guan S, Deng WJ, etal. Clinical study of comparing LP and TP regimens in the treatment of advanced non-small cell lung cancer. Chinese-German J Clin Oncol. 2010;9:198-200.
11. Zhang Q, Huang XE, Gao LL. A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors. Biomed Pharmacother. 2009;63:603-607.
12. Holvoet C, Vander HY, Lories G, etal. Preparation and evaluation of paclitaxel-containing liposomes. Pharmazie. 2007;62:126-132.
13. Yang T, Cui FD, Chai MK, etal. Liposome formulation of paclitaxel with enhanced solubility and stability. Drug Deliv. 2007;14: 301-308.
14. Stinchcombe TE. Nanoparticle albumin-bound paclitaxel: a novel Cremophor EL-free formulation of paclitaxel. Nanomedicine (Lond). 2007;2:415-423.
15. Hureaux J, Lagarce F, Gagnadoux F, etal. Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel. Eur J Pharm Biopharm. 2009;73:239-246.
16. Yang T, Choi MK, Cui FD, etal. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. Pharm Res. 2007;24:2402-2411.
17. Weiner AL. Liposomes as carriers for polypeptides. Adv Drug Deliv Rev. 1989;3:307-341.
18. Zhao PQ, Wang HJ, Yu M, etal. Paclitaxel-loaded, folic-acid-targeted and TAT-peptide-conjugated polymeric liposomes: in vitro and in vivo evaluation. Pharm Res. 2010;27:1914-1926.
19. Meng SY, Su B, Li W, etal. Integrin-targeted paclitaxel nanoliposomes for tumor therapy. Med Oncol. 2011;28:1180-1187.
20. Sharma A, Mayhew E, Straubinger RM. Antitumor effect of Taxol-containing liposomes in a Taxol-resistant murine tumor model. Cancer Res. 1993;53:5877-5881.
21. Balasubramanian SV, Straubinger RM. Taxol-lipid interactions: Taxol-dependent effects on the physical properties of model membranes. Biochemistry. 1994;33:8941-8947.
22. Sharma A, Sharma US, Straubinger RM. Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia. Cancer Lett. 1996;107:265-272.
23. Lin YB, Xie R, Lin YZ. Therapeutic effect of paclitaxel liposome combined with cisplatin for III-IV degrees of cervical cancer. Chin J Woman Child Health Res (Chinese). 2008;19:571-573.
24. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006;1:297-315.
25. Torchilin VP, Trubetskoy VS. Which polymers can make nanoparticulate drug carriers long-circulating? Adv Drug Deliv Rev. 1995;16: 141-155.
26. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethylene glycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990;268:235-237.
27. Blume G, Cevc G. Molecular mechanism of the lipid vesicle longevity in vivo. Biochim Biophys Acta. 1993;1146:157-168.
28. Senior J, Delgado C, Fisher D, Tilcock C, Gregoriadis G. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly (ethylene glycol)-coated vesicles. Biochim Biophys Acta. 1991;1062:77-82.
29. Park J. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 2002;4:95-99.
30. Yang T, Cui FD, Choi MK, etal. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm. 2007;338:317-326.
31. Yoshizawa Y, Kono Y, Ogawara K, etal. PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. Int J Pharm. 2011;412:132-141.
32. Crosasso P, Ceruti M, Brusa P, Arpicco S, Dosio F, Cattel L. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J Control Release. 2000;63: 19-30.
33. Huang Y, Chen XM, Xiang B, etal. Antiangiogenic activity of sterically stabilized liposomes containing paclitaxel (SSL-PTX): in vitro and in vivo. AAPS Pharm Sci Tech. 2010;11:752-759.
34. Penault-Llorca F, Bertucci F, Adélaïde J, etal. Expression of FGF and FGF receptor genes in human breast cancer. Int J Cancer. 1995;61:170-176.
35. Danielsen T, Rofstad EK. VEGF, bFGF and EGF in the angiogenesis of human melanoma xenografts. Int J Cancer. 1998;76:836-841.
36. Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer. 2004;11:709-724.
37. He Q, Wei Y, Tian L, etal. Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem. 2003;278:21831-21836.
38. Chen X, Wang X, Wang Y, etal. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. J Control Release. 2010;145:17-25.
39. Cai L, Qiu N, Li X, etal. A novel truncated basic fibroblast growth factor fragment-conjugated poly (ethylene glycol)-cholesterol amphiphilic polymeric drug delivery system for targeting to the FGFR-overexpressing tumor cells. Int J Pharm. 2011;408:173-182.
40. Sharma A, Mayhew E, Bolcsak L, etal. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int J Cancer. 1997;71:103-107.
41. Savva M, Duda E, Huang L. A genetically modified recombinant tumor necrosis factor-α conjugated to the distal terminals of liposomal surface grafted polyethyleneglycol chains. Int J Pharm. 1999;184: 45-51.
42. Redd WH, Montgomery GH, DuHamel KN. Behavioral intervention for cancer treatment side effects. J Natl Cancer Inst. 2001;93:810-823.
43. Cheong I, Huang X, Bettegowda C, etal. A bacterial protein enhances the release and efficacy of liposomal cancer drugs. Science. 2006;314: 1308-1311.
44. Lotfi-Jam K, Carey M, Jefford M, Schofield P, Charleson C, Aranda S. Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. J Clin Oncol. 2008;26: 5618-5629.
45. Dharap S, Wang Y, Chandna P, etal. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci U S A. 2005;102:12962-12967.
46. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 2005;19:311-330.
47. Suo T, Ge W, Zhang JZ, etal. 17 cases of advanced non-small cell lung cancer treated with paclitaxel liposome plus nedaplatin. Chinese-German Journal of Clinical Oncology. 2012;11:196-198.
48. Torchilin VP, Levchenko TS, Rammohan R, Papahadjopoulos-Sternberg B, D'Souza GG. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci U S A. 2003;100:1972-1977.
49. Yu W, Pirollo KF, Yu B, etal. Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. Nucleic Acids Res. 2004;32(5):e48.
50. Kawakami K, Kawakami M, Puri RK. IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer. J Immunol. 2002;169:7119-7126.
51. Nakase M, Inui M, Okumura K, Kamei T, Nakamura S, Tagawa T. p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome. Mol Cancer Ther. 2005;4:625-631.
52. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53: 283-318.
53. Senior J, Gregoriadis G. Is half-life of circulating liposomes determined by changes in their permeability? FEBS Lett. 1982;145:109-114.
54. Volanakis JE, Wirtz KWA. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers. Nature. 1979;281:155-157.
55. Chonn A, Cullis P, Devine D. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol. 1991;146:4234-4241.
56. Devine DV, Bradley AJ. The complement system in liposome clearance: can complement deposition be inhibited? Adv Drug Deliv Rev. 1998; 32:19-29.
57. Lundberg B, Risovic V, Ramaswamy M, Wasan K. A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. J Control Release. 2003;86:93-100.
58. Gabizon A, Horowitz AT, Goren D, etal. Targeting folate receptor with folate linked to extremities of poly (ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug Chem. 1999;10:289-298.
59. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta. 1995; 1233:134-144.
60. Gustafson DL, Merz AL, Long ME. Pharmacokinetics of combined doxorubicin and paclitaxel in mice. Cancer Lett. 2005;220:161-169.